same drug, different label) If you have moderate obesity (BMI 30 to 35): Semaglutide (Ozempic for diabetes, Wegovy for obesity) or liraglutide (Victoza for diabetes, Saxenda for obesity) If you want the simplest regimen: Once-weekly semaglutide or tirzepatide Goal: Minimize injection frequency Once weekly: Semaglutide, tirzepatide, dulaglutide, efpeglenatide, retatrutide Every two weeks (pipeline): Ecnoglutide (pending approval) Oral (no injections): Semaglutide (Rybelsus) or orforglipron (Orfoglip) Goal: Minimize gastrointestinal side effects Lower nausea profile: Tirzepatide (dual agonist
Change history 06 April 2024 This article has been retracted
Studies show that up to 85% of patients taking GLP-1 receptor agonists experience gastrointestinal adverse effects
Front Endocrinol (2022) 13:789008
Consult your physician or a qualified healthcare professional before use, especially if you are pregnant, breastfeeding, taking medication, or have a medical condition
Clin Chem 2005